What is it about?
Drugs that target B7-H4 have entered clinical trials and are a promising new strategy for treating patients with cancer. This manuscript summarizes the published results so far of B7-H4-targeted agents in clinical trials for cancer patients.
Featured Image
Read the Original
This page is a summary of: B7 Homolog 4 (B7-H4)-Directed Agents in Oncology Clinical Trials: A Review, Journal of Immunotherapy and Precision Oncology, April 2025, Innovative Healthcare Institute,
DOI: 10.36401/jipo-24-34.
You can read the full text:
Contributors
Be the first to contribute to this page
